title: Do Ovarian Cancer Patients with a Family History of Cancer (Suspected BRCA1 or BRCA2 Mutation) Suffer Greater Chemotherapy Toxicity?
abstract: OBJECTIVE
  Few studies have examined toxicity from potentially curative chemotherapy in ovarian cancer patients at risk for breast cancer susceptibility (BRCA) mutation.
  
  
  RESULTS
  Ninety-four of the 482 patients appeared at risk for a mutation based on family history and 23 had a confirmed mutation. Hospitalization or emergency department visits were not increased based on family history with odds ratios (95% confidence intervals) of 0.88 (0.52, 1.45) (p =.62) and 0.90 (0.49, 1.58) (p =.71), respectively; similar findings were observed with confirmed mutations. Trends favored improved survival.
  
  
  CONCLUSIONS
  Concern for a BRCA mutation should not preclude full dose chemotherapy in ovarian cancer patients treated with curative intent.
authors: a Department of Medicine , Mayo Clinic , Rochester , Minnesota , USA.
authors: Heidi
authors: H
authors: Egloff
authors: b Department of Oncology , Mayo Clinic , Rochester , Minnesota , USA.
authors: Aminah
authors: A
authors: Jatoi
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D061325:Hereditary Breast and Ovarian Cancer Syndrome / Q000188:drug therapy / Q000235:genetics; D006760:Hospitalization; D006801:Humans; D008875:Middle Aged; D009154:Mutation; D009367:Neoplasm Staging; D016017:Odds Ratio; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology / Q000235:genetics*; D010597:Pharmacogenetics; D000071184:Pharmacogenomic Variants; D011379:Prognosis; D016896:Treatment Outcome
keywords: Ovarian cancer; chemotherapy; treatment